Publication & Citation Trends
Publications
0 total
Carcinoma of the Lung
Cited by 0
Semantic Scholar
Phase II Oncology Trials: Perspective from Industry
Cited by 0
Semantic Scholar
A rank-based randomized phase II design when the phase III design is based on overall survival (OS).
Cited by 0
Semantic Scholar
Prognostic value of waterfall plots with the addition of nontarget lesion data.
Cited by 1
Semantic Scholar
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.
Cited by 34
Semantic Scholar
A Review of: “ Controversial Statistical Issues in Clinical Trials , by S.-C. Chow”
Cited by 0
Semantic Scholar
A Review of: “ Modeling Survival Data Using Frailty Models , by D. D. Hanagal”
Cited by 1
Semantic Scholar
Clinical importance of including new and nontarget lesion assessment of disease progression (PD) to predict overall survival (OS): Implications for randomized phase II study design.
Cited by 4
Semantic Scholar
Research Topics
HER2/EGFR in Cancer Research
(17)
Lung Cancer Treatments and Mutations
(13)
Chronic Lymphocytic Leukemia Research
(10)
Statistical Methods in Clinical Trials
(9)
Lung Cancer Research Studies
(7)
Affiliations
Buffalo State University
Universitat Autònoma de Barcelona
Novartis (Switzerland)
Pennsylvania State University
United States Department of Veterans Affairs